Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Fabrazyme

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Company presented results of its pivotal Phase III study in 58 patients with Fabry disease at the American Society of Human Genetics meeting in Philadelphia Oct. 5. Twenty of 29 patients treated every two weeks for 20 weeks with intravenous agalsidase beta achieved a score of zero on a scale of 0-3 measuring the level of GL-3 in the kidney vasculature. The score indicated that patients' "blood vessels were restored to a near normal state," providing "strong evidence that the kidney should function normally as a result of treatment," the company said. Genzyme expects approval for its BLA, submitted June 23, around the end of the yea
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel